HowardIScherMD

Cancer Genetics/Cancer Risk Assessment, Genitourinary Oncology, Hematologic Oncology

Head, Biomarker Development Program at Memorial Sloan Kettering Cancer Center

Overview of Dr. Scher

Dr. Howard Scher is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, and Memorial Sloan Kettering Cancer Center. He received his medical degree from New York University Grossman School of Medicine and has been in practice 47 years. Dr. Scher accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(540) 318-7005

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1983
NYU Grossman School of MedicineResidency, Internal Medicine, 1976 - 1980
New York University School of MedicineClass of 1976

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2024 - 2025
NY State Medical License 1977 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Giants of Cancer Care in Genitourinary Oncology 2023
Institute for Scientific Information at Clarivate: Highly Cited Researchers 2022
Highly Cited Researcher – Top 1% Thomas Reuters, 2014-2022
The Chemotherapy Foundation Ezra Greenspan Award 2021
America's Top Doctors Castle Connolly, 2001-2021
Isom Visiting Professor, University of Texas Southwestern Medical Center 2018
Association of American Physicians 2018
Fellow of the American Society of Clinical Oncology (FASCO) 2018
AACR Team Science Award: The Designing AR Inhibitors Team Charles Sawyers, Michael Jung and Howard Scher 2015
Join now to see all

Clinical Trials

Trastuzumab in Treating Patients With Prostate Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 2
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Start of enrollment: 1999 Jul 01
Completed
Phase 1
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 1
A Phase I Single Ascending Dose Trial of MLN2704 (DM1 Conjugated Monoclonal Antibody MLN591) in Subjects With Metastatic Androgen Independent Prostate Cancer Start of enrollment: 2002 Oct 01
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 1, Phase 2
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) Start of enrollment: 2006 Jan 01
Terminated
Phase 3
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Start of enrollment: 2006 Nov 01
Completed
Phase 2
An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Start of enrollment: 2007 Jun 01
Completed
Phase 2
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Start of enrollment: 2007 Jul 23
Completed
Phase 1
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data Start of enrollment: 2004 May 01
Completed
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle Start of enrollment: 2001 Jul 01
Completed
Phase 2
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2008 May 01
Completed
Phase 3
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 1
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease Start of enrollment: 2016 Apr 19
Terminated
Phase 3
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 2
A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07
Terminated
Phase 2
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer Start of enrollment: 2019 Jul 11
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer Start of enrollment: 2024 Mar 28
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.
Matthew C Dallos, Aleksandar Z Obradovic, Patrick McCann, Nivedita Chowdhury, Aditya Pratapa
Clinical Cancer Research. 2024-11-15
1 citations
Automated real-world data integration improves cancer outcome prediction.
Justin Jee, Christopher Fong, Karl Pichotta, Thinh Ngoc Tran, Anisha Luthra
Nature. 2024-11-06
Two decades of advances in clinical oncology - lessons learned and future directions.
Susana Banerjee, Christopher M Booth, Eduardo Bruera, Markus W Büchler, Alexander Drilon
Nature Reviews. Clinical Oncology. 2024-11-01

Lectures

CTC versus biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts).
2019 ASCO Annual Meeting - 6/1/2019
Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outc...
2019 ASCO Annual Meeting - 6/1/2019
Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Tumor Copy Number Alteration Burden Is a Pan-Cancer Prognostic Factor Associated with Recurrence and DeathSeptember 2018

Press Mentions

Triplet Better Than Doublet in mCSPC? Not Always, Say ExpertsMarch 3rd, 2023
Prostate Cancer CTC PSMA Status Could Guide TherapyOctober 3rd, 2022
Taking the Road Less Traveled Toward Clinical Research in Prostate Cancer with Michael J. Morris, MDJuly 27th, 2022
Join now to see all

Grant Support

Spore In Prostate CancerNational Cancer Institute2009–2011
Mechanism Based Therapy For Prostate CancerNational Cancer Institute2001–2002
Biologic Effects Of 17aa GeldanamycinNational Cancer Institute1999–2000

Professional Memberships

American College of Physicians - ACP
Member
Alpha Omega Alpha Honor Medical Society - AOA
Member
American Association for Cancer Research - AACR
Member
American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Health Net California Large Group PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment